



Australian Government

Department of Health and Aged Care

Fifth Report on Key Performance Measures (KPM)

for the

Seventh Community Pharmacy Agreement (7CPA)

July 2024

Contents

Index of Tables	2
Introduction	3
Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians.	4
a) Provision of pharmaceutical benefits in accordance with applicable laws, regulations, professional standards, codes and other requirements (7CPA, Clause 7).....	4
b) Transparency of charges (7CPA, Clause 4.3).	14
c) Closing the Gap (CTG) PBS Co-Payment Program (7CPA, Clause 10).	15
d) Support the uptake of electronic prescription arrangements (7CPA, Clause 9.4).	16
Objective 2: Continue to supply National Diabetes Services Scheme (NDSS) products through community pharmacies	17
The National Diabetes Services Scheme (NDSS) (7CPA, Clause 6 and 8).	17
Objective 3: Support professional initiatives for pharmacists to better fulfil their current scope of practice.	18
a) Pharmaceutical Society of Australia (PSA) Professional Practice Standards (PPS), Practice Guidelines, and Code of Ethics (CoE) (7CPA, Clause 14).	18
b) Accreditation of pharmacists for undertaking medication reviews.....	19
Objective 4: Ensure all Australians have access to pharmacy services and programs that support the safe and quality use of medicines	21
Objective 5: Support access to medicines and pharmacy services for people in regional, rural and remote areas	23

Index of Tables

Table 1(a)-1: Total PBS Expenditure by Patient Category (s90 Pharmacies).....	5
Table 1(a)-2: PBS Prescription volumes by Patient Category (s90 Pharmacies).....	5
Table 1(a)-3: PBS Government Cost by Patient Category (s90 Pharmacies)	6
Table 1(a)-4: RPBS and PBS Prescription volumes for DVA patients (s90 Pharmacies)	6
Table 1(a)-5: RPBS and PBS Government Cost for DVA patients (s90 Pharmacies).....	6
Table 1(a)-6: Patient Contribution and Government Cost by Patient Category (s90 Pharmacies)	7
Table 1(a)-7: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 January – 30 June 2022	8
Table 1(a)-8: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 July – 31 December 2022.....	9
Table 1(a)-9: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 January – 30 June 2023	10
Table 1(a)-10: Discounted and Non-Discounted PBS/RPBS Prescriptions (s90 Pharmacies)	11
Table 1(a)-11: Discount Range for PBS/RPBS prescriptions (s90 Pharmacies).....	11
Table 1(a)-12: Remuneration to s90 Pharmacies and wholesalers for PBS/RPBS Prescriptions	12
Table 1(a)-13: Volume and Expenditure of PBS items supplied in bulk and individually for clients of Remote Area Aboriginal Health Services (RAAHS) by state/territory	13
Table 1(c): Total number of PBS items and expenditure for CTG PBS Co-Payment Program across states and territories	15
Table 1(d): Total expenditure on Electronic Prescription Fees	Error! Bookmark not defined.
Table 2: NDSS Registrants, Community pharmacy Access Points and handling fees paid	17
Table 3(b)-1: Number and percentage of accredited registered pharmacists eligible to provide HMR and RMMR	19
Table 3(b)-2: Number and percentage of accredited pharmacists actively providing HMRs and RMMRs	20
Table 4-1: Total number and expenditure for Community Pharmacy Programs and Services	21
Table 4-2: Number of participating service providers and expenditure recorded for IHSPS Program, QUMAX and S100 Pharmacy Support Allowance.....	Error! Bookmark not defined.
Table 5: Number of participating service providers and expenditure recorded for regional, rural and remote pharmacy services	24

Introduction

Key Performance Measures (KPM) for the Seventh Community Pharmacy Agreement (7CPA) were developed as an evaluation framework for operation of the 7CPA. The KPM aim to enable Government, the pharmacy sector and the community to assess impacts of the 7CPA, based on the available evidence.

The KPM were a new undertaking under the 7CPA. No other evaluation mechanisms had been developed under previous Community Pharmacy Agreements. As no specific funding was made available under the 7CPA for monitoring and evaluation, the KPM have been confined to measures that stem from existing processes, available data and resources, with no additional costs to Government.

The KPM were developed in collaboration between the Department and key stakeholders including the Pharmacy Guild of Australia, the Pharmaceutical Society of Australia, the Consumers Health Forum of Australia, and the National Aboriginal Community Controlled Health Organisation.

KPM reports are published on a biannual basis, subject to the availability of required data.

The KPM report monitors key objectives and outcomes for the 7CPA to:

1. Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians
2. Continue to supply National Diabetes Services Scheme (NDSS) products through community pharmacies
3. Support professional initiatives for pharmacists to better fulfil their current scope of practice
4. Ensure all Australians have access to pharmacy services and programs that support the safe and quality use of medicines; and
5. Support access to medicines and pharmacy services for Australians in regional, rural, and remote areas.

This is the fifth KPM report, adding information for **1 July – 31 December 2023** to previously reported data.

The information in this document should be read in conjunction with the [7CPA – Key Performance Measures and monitoring arrangements](#) and [Key Policy Principles – KPM for 7CPA](#), which are each available on the Department of Health and Aged Care's [website](#). Earlier KPM reports for the 7CPA can also be accessed at: <https://www.health.gov.au/resources/collections/7cpa-key-performance-measures>.

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians.

a) **Provision of pharmaceutical benefits in accordance with applicable laws, regulations, professional standards, codes and other requirements (7CPA, Clause 7).**

The following tables present information on:

- Total prescriptions and expenditure for s90 pharmacies¹, for PBS and Repatriation Pharmaceutical Benefits Scheme (RPBS) items by patient category and state / territory – *Tables 1(a)-1, 1(a)-2, 1(a)-3, 1(a)-4, 1(a)-5, 1(a)-7, 1(a)-8 and 1(a)-9*
- Patient contribution and Government cost for PBS items dispensed by s90 pharmacies – *Table 1(a)-6*
- Over and under co-payment PBS prescriptions for items dispensed by s90 pharmacies – *Table 1(a)-2*
- Discounted and non-discounted PBS/RPBS items dispensed by s90 pharmacies – *Tables 1(a)-10 and 1(a)-11*
- PBS remuneration for s90 pharmacies and wholesalers – *Tables 1(a)-12*
- PBS items supplied in bulk and individually for clients of Remote Area Aboriginal Health Services – *Tables 1(a)-13*

This report has been produced using PBS online claims data maintained by the Department of Health and Aged Care and sourced from Services Australia. Data were extracted on 13 May 2024, unless otherwise indicated. Please note that:

- PBS data does not capture over-the-counter medicines, private prescriptions (non-PBS prescriptions) or public inpatient prescriptions.
- The figures provided are subject to change due to late claims and adjustments by pharmacies.
- PBS data does not capture over-the-counter drugs, private prescriptions (non-PBS) or public inpatient prescriptions.

¹ “s90 Pharmacies” are those pharmacies operated by a pharmacist approved under section 90 of the *National Health Act 1953* to dispense pharmaceutical benefits from a particular pharmacy premises. Other suppliers include approved doctors (usually practising in isolated areas) and approved hospitals.

Objective 2: Continue to supply National Diabetes Services Scheme (NDSS) products through community pharmacies

Table 1(a)-1: Total PBS Expenditure by Patient Category (s90 Pharmacies)

Patient Category	1 July – 31 December 2022		1 January - 30 June 2023		1 July – 31 December 2023	
	PBS Expenditure	Percentage	PBS Expenditure	Percentage	PBS Expenditure	Percentage
Section 85 - Concessional	\$4,215,967,472	61.7%	\$3,452,204,383	56.4%	\$4,151,214,366	58.6%
Section 85 - General	\$1,694,704,288	24.8%	\$1,708,554,975	27.9%	\$1,861,475,875	26.3%
Doctor's Bag	\$27,535,152	0.4%	\$47,887,952	0.8%	\$59,808,829	0.8%
Section 100	\$897,956,183	13.1%	\$910,224,595	14.9%	\$1,016,760,296	14.3%
Total	\$6,836,163,095	100.0%	\$6,118,871,906	100.0%	\$7,089,259,367	100.0%

Note: Excludes expenditure for RPBS items.

Table 1(a)-2: PBS Prescription volumes by Patient Category (s90 Pharmacies)

Section 85 and Section 100, including Drs Bag and under co-payment prescriptions

Patient Category	1 July – 31 December 2022		1 January - 30 June 2023		1 July – 31 December 2023	
	PBS prescriptions	Percentage	PBS prescriptions	Percentage	PBS prescriptions	Percentage
Concessional Non-Safety Net	45,073,721	39.3%	80,970,922	77.4%	43,584,966	37.1%
Concessional Safety Net	57,883,761	50.5%	12,205,843	11.7%	60,210,511	51.2%
Total Concessional	102,957,482	89.8%	93,176,765	89.0%	103,795,477	88.3%
General Non-Safety Net	8,456,664	7.4%	11,230,282	10.7%	11,543,069	9.8%
General Safety Net	3,124,599	2.7%	66,789	0.1%	1,997,243	1.7%
Total General	11,581,263	10.1%	11,297,071	10.8%	13,540,312	11.5%
Doctors Bag	175,503	0.2%	206,829	0.2%	207,704	0.2%
Total (Over Co-payment)	114,714,248	100.0%	104,680,665	100.0%	117,543,493	100.0%
Under Co-payment scripts	52,647,856		51,438,263		52,303,026	
Total (Over and Under Co-payment)	167,362,104		156,118,928		169,846,519	

Objective 2: Continue to supply National Diabetes Services Scheme (NDSS) products through community pharmacies

Table 1(a)-3: PBS Government Cost by Patient Category (s90 Pharmacies)

Section 85 and Section 100, including Drs Bag and excluding under co-payment prescriptions

Patient Category	1 July – 31 December 2022		1 January – 30 June 2023		1 July – 31 December 2023	
	Government Cost	Percentage	Government Cost	Percentage	Government Cost	Percentage
Concessional Non-Safety Net	\$2,233,738,862	32.7%	\$3,403,105,562	55.6%	\$2,140,879,445	30.2%
Concessional Safety Net	\$2,438,367,984	35.7%	\$499,948,714	8.2%	\$2,528,919,928	35.7%
Total Concessional	\$4,672,106,846	68.3%	\$3,903,054,276	63.8%	\$4,669,799,373	65.9%
General Non-Safety Net	\$1,965,442,682	28.8%	\$2,164,806,327	35.4%	\$2,258,299,050	31.9%
General Safety Net	\$171,078,416	2.5%	\$3,123,351	0.1%	\$101,352,115	1.4%
Total General	\$2,136,521,098	31.3%	\$2,167,929,678	35.4%	\$2,359,651,164	33.3%
Doctors Bag	\$27,535,152	0.4%	\$47,887,952	0.8%	\$59,808,829	0.8%
Total (Over Co-payment)	\$6,836,163,095	100.0%	\$6,118,871,906	100.0%	\$7,089,259,367	100.0%

Table 1(a)-4: RPBS and PBS Prescription volumes for DVA patients (s90 Pharmacies)

PBS Section 85 and Section 100 and RPBS items for DVA patients, excluding under co-payment prescriptions

Patient Category	1 July – 31 December 2022		1 January – 30 June 2023		1 July – 31 December 2023	
	Subsidised prescriptions	Percentage	Subsidised prescriptions	Percentage	Subsidised prescriptions	Percentage
Repatriation Non-Safety Net	1,231,889	34.0%	2,751,960	82.5%	1,185,076	33.2%
Repatriation Safety Net	2,395,176	66.0%	582,780	17.5%	2,389,701	66.8%
Total Repatriation	3,627,065	100.0%	3,334,740	100.0%	3,574,777	100.0%

Table 1(a)-5: RPBS and PBS Government Cost for DVA patients (s90 Pharmacies)

PBS Section 85 and Section 100 and RPBS items for DVA patients, excluding under co-payment prescriptions

Patient Category	1 July – 31 December 2022		1 January – 30 June 2023		1 July – 31 December 2023	
	Government Cost	Percentage	Government Cost	Percentage	Government Cost	Percentage
Repatriation Non-Safety Net	\$71,275,175	42.2%	\$122,069,789	83.8%	\$71,537,014	41.9%
Repatriation Safety Net	\$97,664,503	57.8%	\$23,658,202	16.2%	\$99,160,508	58.1%
Total Repatriation	\$168,939,678	100.0%	\$145,727,991	100.0%	\$170,697,522	100.0%

Table 1(a)-6: Patient Contribution and Government Cost by Patient Category (s90 Pharmacies)

Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Patient Category	1 July – 31 December 2022		1 January – 30 June 2023		1 July – 31 December 2023	
	Patient Contribution*	Government Cost	Patient Contribution*	Government Cost	Patient Contribution*	Government Cost
Concessional Non-Safety Net	\$293,847,652	\$2,233,738,862	\$569,560,783	\$3,403,105,562	\$304,099,210	\$2,140,879,445
Concessional Safety Net	\$0	\$2,438,367,984	\$0	\$499,948,714	\$0	\$2,528,919,928
Total Concessional	\$293,847,652	\$4,672,106,846	\$569,560,783	\$3,903,054,276	\$304,099,210	\$4,669,799,373
General Non-Safety Net	\$321,066,551	\$1,965,442,682	\$309,229,699	\$2,164,806,327	\$319,099,945	\$2,258,299,050
General Safety Net	\$20,529,445	\$171,078,416	\$444,541	\$3,123,351	\$13,739,972	\$101,352,115
Total General	\$341,595,996	\$2,136,521,098	\$309,674,240	\$2,167,929,678	\$332,839,917	\$2,359,651,164
Total (excl. Drs Bag)	\$635,443,648	\$6,808,627,944	\$879,235,022	\$6,070,983,954	\$636,939,127	\$7,029,450,538
Doctors Bag	\$0	\$27,535,152	\$0	\$47,887,952	\$0	\$59,808,829
Total (Incl. Drs Bag)	\$635,443,648	\$6,836,163,095	\$879,235,022	\$6,118,871,906	\$636,939,127	\$7,089,259,367

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Objective 2: Continue to supply National Diabetes Services Scheme (NDSS) products through community pharmacies

Table 1(a)-7: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 July – 31 December 2022

Section 85 and Section 100, excluding Drs Bag and excluding under co-payment prescriptions

PBS Prescriptions									
Categories	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	Australia
Concessional Non-Safety Net	14,315,616	11,165,738	9,614,120	3,742,884	4,300,192	1,240,785	219,860	474,526	45,073,721
Concessional Safety Net	19,119,090	14,237,338	11,939,679	4,883,255	5,258,595	1,723,887	128,049	593,868	57,883,761
General Non-Safety Net	2,786,740	1,994,280	1,754,879	520,491	944,614	187,651	81,633	186,376	8,456,664
General Safety Net	1,057,261	761,460	568,022	206,699	362,108	67,013	10,049	91,987	3,124,599
Total	37,278,707	28,158,816	23,876,700	9,353,329	10,865,509	3,219,336	439,591	1,346,757	114,538,745
Government Cost									
Categories	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	Australia
Concessional Non-Safety Net	\$831,704,665	\$501,275,722	\$429,938,453	\$167,315,936	\$219,417,010	\$52,966,741	\$8,182,341	\$22,937,993	\$2,233,738,862
Concessional Safety Net	\$808,632,435	\$602,860,796	\$481,804,109	\$206,318,343	\$233,622,702	\$73,385,010	\$4,630,726	\$27,113,863	\$2,438,367,984
General Non-Safety Net	\$715,714,696	\$487,108,477	\$339,475,811	\$120,715,366	\$215,484,030	\$37,874,265	\$10,180,168	\$38,889,869	\$1,965,442,682
General Safety Net	\$57,885,521	\$44,257,560	\$28,533,692	\$11,026,931	\$20,066,544	\$3,679,222	\$542,064	\$5,086,881	\$171,078,416
Total	\$2,413,937,318	\$1,635,502,555	\$1,279,752,064	\$505,376,576	\$688,590,287	\$167,905,238	\$23,535,299	\$94,028,607	\$6,808,627,944
Total Cost*									
Categories	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	Australia
Concessional Non-Safety Net	\$924,218,298	\$576,221,671	\$491,562,114	\$191,951,432	\$247,220,939	\$61,015,513	\$9,315,622	\$26,080,926	\$2,527,586,514
Concessional Safety Net	\$808,632,435	\$602,860,796	\$481,804,109	\$206,318,343	\$233,622,702	\$73,385,010	\$4,630,726	\$27,113,863	\$2,438,367,984
General Non-Safety Net	\$818,542,698	\$568,915,178	\$402,790,214	\$141,136,050	\$251,704,159	\$44,658,516	\$12,407,171	\$46,355,246	\$2,286,509,233
General Safety Net	\$64,786,270	\$49,378,892	\$32,184,496	\$12,396,594	\$22,457,887	\$4,104,916	\$597,062	\$5,701,744	\$191,607,860
Total	\$2,616,179,701	\$1,797,376,536	\$1,408,340,933	\$551,802,418	\$755,005,686	\$183,163,955	\$26,950,582	\$105,251,779	\$7,444,071,591

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions (Section 85 and Section 100 prescriptions).

Objective 2: Continue to supply National Diabetes Services Scheme (NDSS) products through community pharmacies

Table 1(a)-8: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 January – 30 June 2023

Section 85 and Section 100, excluding Drs Bag and excluding under co-payment prescriptions

PBS Prescriptions									
Categories	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	Australia
Concessional Non-Safety Net	25,998,999	20,045,798	16,901,741	6,861,386	7,616,778	2,364,772	301,442	880,006	80,970,922
Concessional Safety Net	4,139,270	2,980,183	2,532,124	1,002,625	1,029,663	371,999	22,398	127,581	12,205,843
General Non-Safety Net	3,683,403	2,673,339	2,292,005	698,181	1,285,884	250,605	96,486	250,379	11,230,282
General Safety Net	24,083	18,713	10,610	3,555	6,284	1,132	236	2,176	66,789
Total	33,845,755	25,718,033	21,736,480	8,565,747	9,938,609	2,988,508	420,562	1,260,142	104,473,836
Government Cost									
Categories	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	Australia
Concessional Non-Safety Net	\$1,232,052,373	\$777,337,490	\$662,968,007	\$264,234,685	\$331,660,060	\$87,782,110	\$10,160,052	\$36,910,784	\$3,403,105,562
Concessional Safety Net	\$169,840,476	\$121,691,671	\$100,813,485	\$40,841,636	\$44,433,708	\$15,745,527	\$782,223	\$5,799,990	\$499,948,714
General Non-Safety Net	\$788,058,992	\$532,041,162	\$379,747,847	\$132,488,086	\$237,428,949	\$42,245,534	\$10,635,226	\$42,160,529	\$2,164,806,327
General Safety Net	\$1,087,981	\$964,983	\$480,886	\$127,691	\$301,274	\$55,215	\$6,865	\$98,456	\$3,123,351
Total	\$2,191,039,822	\$1,432,035,306	\$1,144,010,225	\$437,692,098	\$613,823,991	\$145,828,386	\$21,584,367	\$84,969,759	\$6,070,983,954
Total Cost*									
Categories	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	Australia
Concessional Non-Safety Net	\$1,413,502,210	\$921,936,438	\$780,070,242	\$312,932,292	\$385,016,643	\$104,229,952	\$11,787,741	\$43,190,828	\$3,972,666,344
Concessional Safety Net	\$169,840,476	\$121,691,671	\$100,813,485	\$40,841,636	\$44,433,708	\$15,745,527	\$782,223	\$5,799,990	\$499,948,714
General Non-Safety Net	\$887,227,722	\$610,080,062	\$440,469,911	\$152,216,446	\$273,162,675	\$48,857,606	\$12,681,055	\$49,340,547	\$2,474,036,025
General Safety Net	\$1,246,581	\$1,096,405	\$547,396	\$150,795	\$342,176	\$62,917	\$7,880	\$113,742	\$3,567,892
Total	\$2,471,816,989	\$1,654,804,576	\$1,321,901,034	\$506,141,169	\$702,955,201	\$168,896,001	\$25,258,898	\$98,445,107	\$6,950,218,976

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions (S85 and S100 prescriptions).

Objective 2: Continue to supply National Diabetes Services Scheme (NDSS) products through community pharmacies

Table 1(a)-9: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 July – 31 December 2023

Section 85 and Section 100, excluding Drs Bag and excluding under co-payment prescriptions

PBS Prescriptions									
Categories	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	Australia
Concessional Non-Safety	13,865,412	10,720,036	9,265,546	3,604,742	4,234,468	1,191,041	213,843	489,878	43,584,966
Concessional Safety Net	19,773,910	14,810,473	12,438,650	5,130,511	5,487,377	1,796,155	141,492	631,943	60,210,511
General Non-Safety Net	3,754,261	2,771,205	2,367,930	715,552	1,327,928	250,413	102,561	253,219	11,543,069
General Safety Net	686,820	475,226	365,722	123,956	235,359	44,822	7,069	58,269	1,997,243
Total	38,080,403	28,776,940	24,437,848	9,574,761	11,285,132	3,282,431	464,965	1,433,309	117,335,789
Government Cost									
Categories	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	Australia
Concessional Non-Safety	\$814,259,317	\$474,507,731	\$412,651,631	\$154,861,844	\$207,263,766	\$47,564,443	\$7,784,440	\$21,986,272	\$2,140,879,445
Concessional Safety Net	\$834,318,143	\$624,155,403	\$506,713,571	\$213,648,400	\$240,522,947	\$75,555,568	\$4,989,939	\$29,015,957	\$2,528,919,928
General Non-Safety Net	\$819,956,801	\$560,614,223	\$396,978,933	\$137,955,283	\$246,445,934	\$42,210,188	\$11,162,818	\$42,974,868	\$2,258,299,050
General Safety Net	\$34,728,028	\$24,611,636	\$17,874,596	\$6,290,564	\$12,102,745	\$2,231,997	\$297,254	\$3,215,295	\$101,352,115
Total	\$2,503,262,290	\$1,683,888,992	\$1,334,218,732	\$512,756,091	\$706,335,392	\$167,562,197	\$24,234,451	\$97,192,393	\$7,029,450,538
Total Cost*									
Categories	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	Australia
Concessional Non-Safety	\$910,117,946	\$551,648,583	\$476,128,825	\$180,250,864	\$236,593,925	\$55,820,072	\$8,952,243	\$25,466,197	\$2,444,978,655
Concessional Safety Net	\$834,318,143	\$624,155,403	\$506,713,571	\$213,648,400	\$240,522,947	\$75,555,568	\$4,989,939	\$29,015,957	\$2,528,919,928
General Non-Safety Net	\$921,481,236	\$641,631,938	\$460,065,921	\$158,227,314	\$283,546,192	\$48,839,791	\$13,357,867	\$50,248,735	\$2,577,398,995
General Safety Net	\$39,409,781	\$28,013,122	\$20,305,007	\$7,151,109	\$13,733,258	\$2,526,217	\$327,527	\$3,626,066	\$115,092,087
Total	\$2,705,327,106	\$1,845,449,046	\$1,463,213,325	\$559,277,688	\$774,396,322	\$182,741,647	\$27,627,576	\$108,356,955	\$7,666,389,665

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions (S85 and S100 prescriptions).

Objective 2: Continue to supply National Diabetes Services Scheme (NDSS) products through community pharmacies

Table 1(a)-10: Discounted and Non-Discounted PBS/RPBS Prescriptions (s90 Pharmacies)

Section 85 and Section 100, excluding Drs Bag and under co-payment prescriptions

Report Period	Prescription Type	Concessional		General		RPBS		Total	
		Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
1 July – 31 December 2022	Discounted	17,211,191	16.7%	3,349,610	28.9%	369,922	10.2%	20,930,723	17.7%
	Non-discounted	85,746,291	83.3%	8,231,653	71.1%	3,257,143	89.8%	97,235,087	82.3%
	Grand Total	102,957,482	100.0%	11,581,263	100.0%	3,627,065	100.0%	118,165,810	100.0%
1 January – 30 June 2023	Discounted	23,600,749	25.3%	3,366,076	29.8%	540,914	16.2%	27,507,739	25.5%
	Non-discounted	69,576,016	74.7%	7,930,995	70.2%	2,793,826	83.8%	80,300,837	74.5%
	Grand Total	93,176,765	100.0%	11,297,071	100.0%	3,334,740	100.0%	107,808,576	100.0%
1 July – 31 December 2023	Discounted	15,072,916	14.5%	3,753,338	27.7%	315,890	8.8%	19,142,144	15.8%
	Non-discounted	88,722,561	85.5%	9,786,974	72.3%	3,258,887	91.2%	101,768,422	84.2%
	Grand Total	103,795,477	100.0%	13,540,312	100.0%	3,574,777	100.0%	120,910,566	100.0%

Table 1(a)-11: Discount Range for PBS/RPBS prescriptions (s90 Pharmacies)

Section 85 and Section 100, excluding Drs Bag and under co-payment prescriptions

Report Period	Discount Range	Concessional		General		RPBS		Total	
		Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
1 July – 31 December 2022	\$1.00	16,822,212	97.7%	3,293,732	98.3%	360,617	97.5%	20,476,561	97.8%
	0.50 - < \$1.00	249,293	1.4%	31,793	0.9%	5,700	1.5%	286,786	1.4%
	< 50c	59,870	0.3%	7,178	0.2%	1,586	0.4%	68,634	0.3%
	Other	79,816	0.5%	16,907	0.5%	2,019	0.5%	98,742	0.5%
	Grand Total	17,211,191	100.0%	3,349,610	100.0%	369,922	100.0%	20,930,723	100.0%
1 January – 30 June 2023	\$1.00	22,975,129	97.3%	3,274,999	97.3%	524,945	97.0%	26,775,073	97.3%
	0.50 - < \$1.00	385,018	1.6%	41,766	1.2%	9,430	1.7%	436,214	1.6%
	< 50c	111,915	0.5%	37,039	1.1%	3,607	0.7%	152,561	0.6%
	Other	128,687	0.5%	12,272	0.4%	2,932	0.5%	143,891	0.5%
	Grand Total	23,600,749	100.0%	3,366,076	100.0%	540,914	100.0%	27,507,739	100.0%
1 July – 31 December 2023	\$1.00	14,743,765	97.8%	3,664,312	97.6%	307,863	97.5%	18,715,940	97.8%
	0.50 - < \$1.00	78,957	0.5%	12,171	0.3%	2,117	0.7%	93,245	0.5%
	< 50c	183,769	1.2%	63,746	1.7%	4,486	1.4%	252,001	1.3%
	Other	66,425	0.4%	13,109	0.3%	1,424	0.5%	80,958	0.4%
	Grand Total	15,072,916	100.0%	3,753,338	100.0%	315,890	100.0%	19,142,144	100.0%

Objective 2: Continue to supply National Diabetes Services Scheme (NDSS) products through community pharmacies

Table 1(a)-12: Remuneration to s90 Pharmacies and wholesalers for PBS/RPBS Prescriptions

Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Pharmacy remuneration recognises the cost to pharmacist for the purchase of medicines; the administration, handling and storage costs entailed in dispensing medicines by the pharmacy (including associated infrastructure costs); and a pharmacist's specialised skills in dispensing the medicines.

Expenses for PBS and RPBS Prescriptions	1 July – 31 December 2022	1 January – 30 June 2023	1 July – 31 December 2023
Medicines Price			
Ex-Manufacturer Price	\$5,145,138,722	\$4,817,893,119	\$5,200,786,178
Wholesale Mark-Up	\$274,719,201	\$252,374,026	\$271,322,293
Total Price to Pharmacist	\$5,419,857,923	\$5,070,267,145	\$5,472,108,471
Pharmacy Costs			
Administration, Handling and Infrastructure (AHI) fee	\$654,773,696	\$596,896,277	\$695,446,442
Dispensing Fee	\$916,693,173	\$835,975,364	\$1,003,987,005
Dangerous Drug Fee	\$21,644,848	\$22,521,556	\$27,405,790
Wastage Fee	\$3,438,981	\$3,441,854	\$2,281,797
Container Fee	\$426,710	\$375,963	\$380,945
Total Pharmacy Remuneration	\$1,596,977,408	\$1,459,211,014	\$1,729,501,979
Total Cost	\$7,016,835,331	\$6,529,478,159	\$7,201,610,451

Data is for PBS and RPBS prescriptions claimed by community pharmacies and friendly societies for both Section 85 and some Section 100 items. It includes Government and patient contributions; Efficient Funding of Chemotherapy (EFC) items dispensed from March 2021; and private and public hospital HSD claims dispensed.

Table 1(a)-13: Volume and Expenditure of PBS items supplied in bulk and individually for clients of Remote Area Aboriginal Health Services (RAAHS) by state/territory

Report Period	RAHHS Supply	NSW/TAS*	NT	QLD	SA	WA	Australia
1 July – 31 December 2022	Total Items**	5,589	526,067	178,418	37,339	256,213	1,003,626
	Total Items Cost	\$142,727	\$13,970,658	\$5,331,177	\$1,015,595	\$6,679,525	\$27,139,682
	Individual Items***	1,526	353,627	113,685	16,278	177,843	662,959
	Individual Items cost	\$7,669	\$1,777,022	\$571,531	\$81,733	\$893,784	\$3,331,739
1 January – 30 June 2023	Total Items**	4,636	549,034	177,302	31,940	243,819	1,006,731
	Total Items Cost	\$112,367	\$14,529,994	\$4,766,765	\$922,122	\$6,394,415	\$26,725,663
	Individual Items***	1,445	368,460	104,098	14,858	151,171	640,032
	Individual Items cost	\$7,283	\$1,857,038	\$524,654	\$74,884	\$761,714	\$3,225,574
1 July – 31 December 2023	Total Items**	5,269	603,486	170,239	31,044	244,546	1,054,584
	Total Items Cost	\$156,146	\$15,832,624	\$4,759,617	\$931,348	\$6,332,532	\$28,012,268
	Individual Items***	1,514	441,619	115,776	14,262	166,230	739,401
	Individual Items cost	\$7,888	\$2,290,010	\$598,429	\$73,949	\$861,273	\$3,831,548

Note: there are no RAAHS data for VIC and ACT.

* Data for NSW and Tasmania have been aggregated to prevent identification due to low number of individual data points available.

** Total Items includes items supplied in bulk and individually.

*** Items supplied individually are taken from the no. of instances of the Patient Specific Medicine Supply Fee (PSMSF) paid for each PBS medicine ordered on a RAAHS prescription, and labelled for an individual patient, for supply through an approved RAAHS.

The PSMSF is paid in addition to the handling fee paid to eligible pharmacies for the supply of bulk PBS medicines to an approved RAAHS.

The PSMSF figures are a subset of the RAAHS figures.

From 1 July 2022 to 30 June 2023 the PSMSF was \$5.04 and from 1 July 2023 to 30 June 2024 the PSMSF was \$5.21.

The PSMSF data has been manually extracted from Services Australia Remote Area Aboriginal Health Services Access data base and is not sourced from official channels.

These data relate to the date claims are processed and may differ from other data provided by Services Australia, including PBS Expenditure data.

PSMSF values may be affected by rounding.

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

b) **Transparency of charges (7CPA, Clause 4.3).**

Clause 4.3 of the Seventh Community Pharmacy Agreement (7CPA) committed the Pharmacy Guild of Australia (Guild) to ensuring that Approved Pharmacists² “make consumers aware, prior to dispensing a Pharmaceutical Benefit, of any Safety Net Recording Fee and Additional Patient Charge to be charged, the fact that the Additional Patient Charge is not Commonwealth initiated, and the total cost to the consumer of that Pharmaceutical Benefit.” During the First Financial Year of the 7CPA, the Guild was required to work with the Department to develop arrangements and processes to support this commitment.

Following discussion at the first meeting of the 7CPA Pharmacy Stakeholder Consultation Committee (PSCC) in October 2020, the Guild worked with the Department to develop arrangements and processes for Approved Pharmacists to make the required disclosures and to notify consumers, prior to dispensing, of the price of the Pharmaceutical Benefit.

The draft communication resources and materials developed by the Guild, consisting of an in-pharmacy poster and supporting Frequently Asked Questions (FAQ), were subsequently discussed at the second PSCC meeting in April 2021, with further consultations between the Department, the Pharmaceutical Society of Australia (PSA), Consumers Health Forum of Australia (CHF) and the National Aboriginal Community Controlled Health Organisation (NACCHO), leading to consumer focus testing hosted by CHF and the Guild.

Following endorsement of the Guild’s communication resources by PSCC in July 2021, the resources were published on the Guild’s [FindaPharmacy](#) website on 1 January 2022, to coincide with annual PBS patient co-payment changes.

The Guild will continue to provide regular updates on progress and uptake of its PBS medicines pricing resources at biannual meetings of the PSCC. Communiqués arising from each meeting of the PSCC are published on the [Department’s website](#).

² An “**approved pharmacist**” means a pharmacist approved under section 90 of the *National Health Act 1953* to dispense pharmaceutical benefits from a particular pharmacy premises.

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

c) Closing the Gap (CTG) PBS Co-Payment Program (7CPA, Clause 10).

The CTG PBS Co-payment program was established in July 2010 to improve access to affordable PBS medicines for Aboriginal and Torres Strait Islander people living with, or at risk of, chronic disease, and who in their doctor's opinion would experience setbacks in the prevention or ongoing management of chronic disease if they did not take the prescribed medicine and would be unlikely to adhere to their medicines regimen without assistance through the program.

When obtaining PBS General Schedule medicines at their local pharmacy, eligible general patients who would normally pay the full PBS co-payment pay the concessional rate and those eligible patients who would normally pay the concessional rate receive their PBS medicines without being required to pay a PBS co-payment.

The following table presents information on the total number of PBS items and expenditure for the CTG PBS Co-Payment Program across states and territories. This report has been produced using PBS online claims data maintained by the Department of Health and Aged Care and sourced from Services Australia.

Table 1(c): Total number of PBS items and expenditure for CTG PBS Co-Payment Program across states and territories*

Pharmacy State/Territory	1 July – 31 December 2022		1 January – 30 June 2023		1 July – 31 December 2023**	
	No. of PBS items	CTG Benefit Amount	No. of PBS items	CTG Benefit Amount	No. of PBS items	CTG Benefit Amount
ACT	37,853	\$304,457	37,760	\$349,442	42,161	\$316,034
NSW	1,685,396	\$10,690,194	1,668,338	\$13,698,941	1,812,176	\$11,165,647
NT	117,191	\$920,885	120,518	\$1,070,568	127,945	\$956,245
QLD	1,330,385	\$8,762,770	1,317,597	\$10,928,872	1,414,472	\$9,178,529
SA	265,021	\$1,565,180	264,734	\$2,081,278	289,600	\$1,669,104
TAS	174,731	\$969,395	176,914	\$1,379,322	192,065	\$1,036,988
VIC	332,423	\$2,068,862	332,954	\$2,695,144	363,344	\$2,219,997
WA	442,448	\$3,015,821	442,309	\$3,686,398	472,931	\$3,112,381
Total	4,385,448	\$28,297,565	4,361,124	\$35,889,965	4,714,694	\$29,654,926

* The data provided is inclusive of PBS and RPBS items and expenditure and excludes Doctor's Bag. ** Data extracted 13 May 2024.

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

d) *Support the uptake of electronic prescription arrangements (7CPA, Clause 9.4).*

Electronic prescribing provides an option for prescribers and their patients to use an electronic prescription as an alternative to a paper prescription. Electronic prescriptions are part of the broader digital health and medicines safety framework and are part of an Australian Government budget measure to make the PBS more efficient. Electronic prescribing aims to provide convenience and choice to patients while improving PBS efficiency, compliance and medicines safety. Electronic prescribing does not fundamentally change existing prescribing and dispensing processes: patients can still choose which pharmacy they attend to fill their prescription; and paper prescriptions are still available.

An Electronic Prescription Fee (EPF) is paid to pharmacies for the dispensing of electronic prescriptions.

Under the 7CPA (clause 9.4), the Commonwealth continues to support the uptake of electronic prescriptions by Approved Pharmacists. Following the first financial year of the 7CPA, the EPF will transition to a direct funding arrangement with Exchange Infrastructure Providers rather than Approved Pharmacists.

The transition to a direct model began with a Request for Information (RFI) to explore the current and future state of Prescription Delivery Services, closing in Oct 2021. Informed by the RFI results, the Government announced the Request for Tender for Electronic Prescription Services (Ref: Health/E21- 576909) to engage a single or multiple providers for ongoing Prescription Delivery Services. The tender closed on 2 June 2022 and in May 2023, the department signed a 4-year contract for Fred IT's eRx Script Exchange to supply the national Prescription Delivery Service from 1 July 2023.

The 15-cent electronic prescription fee (EPF) paid to pharmacies via the Community Pharmacy Agreement will end on 30 June 2023. The ending of the EPF will maintain a cost-neutral arrangement for pharmacies as they will no longer be charged a 15c fee for eligible prescriptions by the Prescription Delivery Services.

Objective 2: Continue to supply National Diabetes Services Scheme (NDSS) products through community pharmacies

The National Diabetes Services Scheme (NDSS) (7CPA, Clause 6 and 8).

Approved community pharmacy Access Points receive a payment of \$1 plus GST for each NDSS product pack supplied to registrants.

Community Service Obligation Distributors (CSODs) receive a payment of \$1 plus GST for each NDSS product pack delivered to NDSS Access Points.

Table 2: NDSS Registrants, Community pharmacy Access Points and handling fees paid

Category	1 July – 31 December 2022	1 January – 30 June 2023	1 July – 31 December 2023
Total No. of NDSS registrants	1,487,300	1,451,094	1,463,772
Registrants registered on the NDSS Gestational Diabetes Mellitus Reminder Register	229,291	185,424	232,259
Total No. of approved community pharmacy NDSS Access Points	5,923	5,724	5,957
<i>Total Access Point Fees Paid</i>	<i>\$3,636,145</i>	<i>\$3,448,246</i>	<i>\$3,553,235</i>

Objective 3: Support professional initiatives for pharmacists to better fulfil their current scope of practice.

a) *Pharmaceutical Society of Australia (PSA) Professional Practice Standards (PPS), Practice Guidelines, and Code of Ethics (CoE) (7CPA, Clause 14).*

Clause 14.2 of the Seventh Community Pharmacy Agreement (7CPA) commits the Pharmaceutical Society of Australia (PSA) and the Department of Health and Aged Care, to working together in relation to the further development of the PSA Code of Ethics that underpins pharmacist practice in Australia.

The Department has chosen not to pursue an update of the PSA Code of Ethics at this time, following a review of PSA's proposal submitted in late 2021.

Clause 14.6 of the 7CPA commits the PSA to continue to maintain the Professional Practice Standards (PPS) and relevant clinical guidelines with the aim of providing pharmacists with practice information to support the safe and quality use of medicines.

PSA launched a Self-assessment and quality improvement implementation program on 14/10/2023 to help pharmacists better understand and implement the standards into their practice.

Objective 3: Support professional initiatives for pharmacists to better fulfil their current scope of practice.

b) **Credentialing of pharmacists for undertaking medication reviews**

Home Medicines Reviews (HMR) and Residential Medication Management Reviews (RMMR) are medication management services initiated and supported by the Australian Government, aimed at supporting the quality use of medicines and assisting in minimising adverse medicine events by helping people understand and manage their medicines. Medication reviews are initiated by a medical practitioner and conducted by a credentialed pharmacist. The HMR involves a credentialed pharmacist making a visit to a patient’s home to provide a medication review service, while the RMMR service is provided to an eligible patient residing in an eligible Residential Care Facility. In both HMR and RMMR, after the initial interview, the credentialed pharmacist provides an HMR or RMMR report respectively to the initiating medical practitioner for consideration of issues raised.

From 21 April 2020, if clinically indicated, up to two follow-up services may be conducted to resolve medication-related problems identified at the initial interview.

Table 3(b)-1: Number and percentage of credentialed registered pharmacists eligible to provide HMR and RMMR

Category	1 July – 31 December 2022		1 January – 30 June 2023		1 July – 31 December 2023	
	Number	Percentage	Number	Percentage	Number	Percentage
Accredited registered pharmacists	2,836 ^a	7.9%	3207 ^c	8.8%	2956 ^e	7.9%
Total No. of registered pharmacists	35,732^b		36,425^d		37,393^f	

*a - as at 19 December 2022. Information sourced from data published by [The Society of Hospital Pharmacists of Australia \(SHPA\)](#), *The Accredited Pharmacist Issue 22/22* dated 19 December 2022 and [Pharmacy Board of Australia \(PBA\)](#).*

b - as of 31 December 2022. Includes 125 pharmacists on the short-term pandemic response sub-register (this register closed on 22 September 2022).

c - as at 11 October 2023. Information sourced from PSA and data published by [SHPA Accredited Pharmacists Directory](#). Please note that the numbers reported are derived from opt-in directories and actual numbers may therefore differ from those shown in the table.

d - as at 30 June 2023. Information sourced from data published by [Pharmacy Board of Australia \(PBA\)](#).

e – Information sourced from Pharmacy Programs Administrator

f – as at 31 December 2023. Information sourced from data published by [Pharmacy Board of Australia \(PBA\)](#).

Note: A credentialed pharmacist can provide both HMR and RMMR services.

Objective 3: Support professional initiatives for pharmacists to better fulfil their current scope of practice

Table 3(b)-2: Number and percentage of credentialed pharmacists actively providing HMRs and RMMRs

Category	1 July – 31 December 2022		1 January - 30 June 2023		1 July – 31 December 2023	
	Number	Percentage	Number	Percentage	Number	Percentage
Average No. of credentialed pharmacists actively providing HMR/RMMR services ^a	1,250	44.1%	1,182	36.9%	1270	42.9%
Total No. of credentialed pharmacists	2,836		3207		2956	

a - Information sourced from [ZCPA - Pharmacy programs data](#) (last updated 23 May 2024) published by the Department of Health and Aged Care.

Objective 4: Ensure all Australians have access to pharmacy services and programs that support the safe and quality use of medicines

Objective 4: Ensure all Australians have access to pharmacy services and programs that support the safe and quality use of medicines

The 7CPA provides funding for professional pharmacy programs and services over the life of the Agreement. These programs include continuation and revision of existing pharmacy programs and services from the 6CPA and include:

- **Medication Adherence Programs:** Dose Administration Aids (DAA) and Staged Supply
- **Medication Management Programs:** MedsCheck, Diabetes MedsCheck, Home Medicines Review (HMR), Residential Medication Management Review (RMMR) and Quality Use of Medicines (QUM) in Residential Aged Care Facilities
- **Aboriginal and Torres Strait Islander Programs:** Indigenous Dose Administration Aids (IDAA) Program and Indigenous Health Services Pharmacy Support (IHSPS) Program

Table 4-1: Total number and expenditure for Community Pharmacy Programs and Services

Program or Service	1 July – 31 December 2022		1 January – 30 June 2023		1 July – 31 December 2023	
	Total Services	Expenditure	Total Services	Expenditure	Total Services	Expenditure
Dose Administration Aids	7,977,630	\$49,368,323	8,232,658	\$50,969,636	8,473,613	\$52,416,629
Indigenous Dose Administration Aids	903,094	\$10,577,216	975,535	\$11,482,991	1,067,425	\$12,601,811
Staged Supply	97,258	\$4,535,245	103,562	\$4,745,436	113,319	\$5,211,658
HMR*	79,891	\$14,732,760	64,607	\$12,597,906	74,024	\$14,635,475
RMMR*	80,010	\$7,857,906	75,875	\$7,463,484	83,167	\$8,107,461
MedsCheck	206,511	\$13,739,179	216,939	\$14,432,954	239,236	\$15,916,370
Diabetes MedsCheck	90,427	\$9,023,714	103,048	\$10,283,172	122,372	\$12,211,502
Quality Use of Medicines in Residential Aged Care Facilities	110 ^a	\$5,694,451	104 ^a	\$5,788,069	107 ^a	\$6,076,049

* Total services for HMR and RMMR programs are inclusive of services paid for first and second follow up.

^a – this item reports the average number of participating service providers for this service in any one month during the reporting period. Please note that it does not represent the number of services provided.

Information sourced from [7CPA - Pharmacy programs data](#) (last updated 23 May 2024) published by the Department of Health and Aged Care.

Objective 4: Ensure all Australians have access to pharmacy services and programs that support the safe and quality use of medicines

Indigenous Health Services Pharmacy Support (IHSPS) Program

The IHSPS Program was created by merging the Quality Use of Medicines Maximised for Aboriginal & Torres Strait Islander People (QUMAX) and S100 Pharmacy Support Allowance programs, which continued from the 6CPA during the first year of the 7CPA (until 30 June 2021).

The IHSPS Program commenced in July 2021.

Table 4-2: Number of registered IHSPS sites and expenditure recorded for IHSPS Program

Program	1 July – 31 December 2022		1 January – 30 June 2023		1 July – 31 December 2023	
	Average No. of registered IHSPS sites	Expenditure	Average No. of registered IHSPS sites	Expenditure	Average No. of registered IHSPS sites	Expenditure
IHSPS Program	228	\$2,584,282	224	\$1,194,096	226	\$2,852,501

Information sourced from [Rural support and Aboriginal and Torres Strait Islander pharmacy programs data](#) (last updated 1 May 2024) published by the Department of Health and Aged Care.

Objective 5: Support access to medicines and pharmacy services for people in regional, rural and remote areas.

Objective 5: Support access to medicines and pharmacy services for people in regional, rural and remote areas

Rural Support Programs are targeted programs and services to support access to PBS medicines and pharmacy services for people living in regional, rural and remote regions of Australia. Services supported under the 7CPA include:

- Regional Pharmacy Maintenance Allowance
- Rural Continuing Professional Education Allowance
- Emergency Locum Service
- Intern Incentive Allowance for Rural Pharmacies
- Incentive Allowance for Rural Pharmacies - Extension Program
- Rural Intern Training Allowance
- Rural Pharmacy Scholarship Scheme
- Rural Pharmacy Scholarship Mentor Scheme
- Rural Pharmacy Liaison Officer Program
- Rural Pharmacy Student Placement Allowance Program and Administrative Support to Pharmacy Schools Scheme
- Aboriginal and Torres Strait Islander Pharmacy Scholarship Scheme

Table 5 (below) provides data on a range of items (e.g., number of active service providers, number of approved claims, number of locum placements etc.) along with the total expenditure for each of the above programs.

Note that service providers differ based on specific programs and include pharmacists, pharmacy educators, universities and pharmacy interns, in addition to rural and remote hospital and community pharmacies.

Objective 5: Support access to medicines and pharmacy services for people in regional, rural and remote areas.

Table 5: Number of items and expenditure recorded for regional, rural and remote pharmacy services

Program	1 July – 31 December 2022		1 January – 30 June 2023		1 July – 31 December 2023	
	Item	Expenditure	Item	Expenditure	Item	Expenditure
Regional Pharmacy Maintenance Allowance (RPMA)*	1,079 ^a	\$9,888,853	1,092 ^a	\$9,916,475	1,137 ^a	\$17,613,378
Rural Continuing Professional Education Allowance (CPE)	76 ^b	\$76,468	132 ^b	\$141,129	135 ^b	\$134,376
Emergency Locum Service (ELS)	36 ^c	\$64,719	42 ^c	\$32,309	51 ^c	\$55,904
Intern Incentive Allowance for Rural Pharmacies (IIARP)	44.5 ^d	\$142,500	75 ^d	\$385,833	80 ^d	\$302,500
Intern Incentive Allowance for Rural Pharmacies - Extension Program (IIARP-EP)	8.5 ^d	\$71,667	11 ^d	\$92,500	7 ^d	\$45,000
Rural Intern Training Allowance (RITA)	73 ^b	\$36,663	62 ^b	\$30,885	99 ^b	\$48,697
Rural Pharmacy Scholarship Scheme (RPSS)	52 ^d	\$251,000	48 ^d	\$247,000	47.5 ^d	\$226,000
Rural Pharmacy Scholarship Mentor Scheme (RPSMS)	80.5 ^d	\$16,500	88 ^d	\$3,375	98.5 ^d	\$15,000
Rural Pharmacy Liaison Officer (RPLO)	9 ^d	\$355,500	9.5 ^d	\$330,600	10 ^d	\$467,700
Rural Pharmacy Student Placement Allowance (RPSPA)	16 ^e	\$273,819	17 ^e	\$82,838	17 ^e	\$470,519
Administrative Support to Pharmacy Schools Scheme (ASPSS)	16 ^e	\$117,500	17 ^e	\$102,985	17 ^e	\$256,167
Aboriginal and Torres Strait Islander Pharmacy Scholarship Scheme (ATSIPSS)	4 ^d	\$30,000	7 ^d	\$52,500	8 ^d	\$55,500

The items reported are; a-Average number of active service providers for RPMA, b- No. of approved claims, c- No. of locum placements, d- Average no. of active participants, e- Average no. of participating universities. This information was sourced from [Rural support and Aboriginal and Torres Strait islander pharmacy programs data](#) (last updated 1 May 2024) published by the Department of Health and Aged Care.

* This information was sourced from [7CPA - Pharmacy program data](#) (last updated 23 May 2024) published by the Department of Health and Aged Care.